Skip to main content

Latest neurology news

17-01-2019 | Multiple sclerosis | News | Article

Early aggressive treatment to delay conversion to secondary progressive MS

The findings from two studies published in JAMA show the benefits of initial disease-modifying therapy and nonmyeloablative haematopoietic stem cell transplantation in delaying conversion to secondary progressive multiple sclerosis.


JAMA 2019; 321: 153–155

JAMA 2019; 321: 165–174

JAMA 2019; 321: 175–187

10-01-2019 | Multiple sclerosis | News | Article

Rituximab shows disability benefits in patients with secondary progressive MS

Rituximab treatment may reduce and delay disability progression in patients with secondary progressive multiple sclerosis, show findings from a comprehensive real-world cohort study.


JAMA Neurol 2019; doi:10.1001/jamaneurol.2018.4239

20-12-2018 | Motor neuron diseases | News | Article

Cannabinoid spray shows anti-spasticity efficacy in motor neuron disease

The oromucosal cannabinoid spray nabiximols has had a positive effect on spasticity symptoms in patients with motor neuron disease in a proof-of-concept trial.


Lancet Neurol 2018; doi:10.1016/ S1474-4422(18)30406-X

Lancet Neurol 2018; doi:10.1016/ S1474-4422(18)30493-9

13-12-2018 | Neurology | Main feed | News

Biomarkers predict cognitive impairment risk

US researchers have used population-based data to predict an individual’s absolute risk of developing cognitive impairment according to imaging-based biomarkers of amyloid and neuronal injury.


Ann Neurol 2018; doi:10.1002/ana.25388

29-11-2018 | Alzheimer's disease | News | Article

Global burden of dementia estimated

The number of people living with dementia globally has more than doubled between 1990 and 2016, estimates the Global Burden of Disease Study 2016.


Lancet Neurol 2018; doi:10.1016/S1474-4422(18)30403-4

Lancet Neurol 2018; doi:10.1016/S1474-4422(18)30456-3

22-11-2018 | Alzheimer's disease | Highlight | Article

Editor's pick

Most patients with Down’s syndrome will have dementia at the time of death

Dementia is the proximate cause of death in 70% of older adults with Down’s syndrome, show findings from a large community-based study published in JAMA Neurology.


JAMA Neurol 2018; doi:10.1001/jamaneurol.2018.3616

JAMA Neurol 2018; doi:10.1001/jamaneurol.2018.3443

15-11-2018 | Alzheimer's disease | News | Article

CSF neurofilament light a ‘preferred’ biomarker for MCI progression

Elevated cerebrospinal fluid neurofilament light levels are associated with an increased risk of mild cognitive impairment, indicate findings from a population-based study.


JAMA Neurol 2018; doi:10.1001/jamaneurol.2018.3459

08-11-2018 | Neurology | Main feed | News

Global burden of motor neuron diseases quantified

High-income countries currently have the highest rates of motor neuron diseases worldwide, and the burden is increasing with the ageing population, shows an analysis of the Global Burden of Diseases, Injuries, and Risk Factors Study 2016.


Lancet Neurol 2018; doi:10.1016/S1474-4422(18)30404-6
Lancet Neurol 2018; doi:10.1016/S1474-4422(18)30398-3

01-11-2018 | Parkinson's disease | News | Article

Dopamine to levodopa-carbidopa switch reduces impulse control disorders in PD

Switching from dopamine agonists to levodopa-carbidopa slow-release formulations reduces impulse control disorders in patients with Parkinson’s disease, shows a multicentre study.


J Neurol Neurosurg Psychiatry 2018; doi:10.1136/jnnp-2018-318942

J Neurol Neurosurg Psychiatry 2018; doi:10.1136/jnnp-2018-319375

25-10-2018 | Multiple sclerosis | News | Article

Medicinal cannabinoids show small antispastic and analgesic benefits for MS patients

The benefits of medicinal cannabinoids for the treatment of spasticity, pain and bladder dysfunction in patients with multiple sclerosis may be limited, suggests a systematic review and meta-analysis.


JAMA Network Open 2018; 1(6): e183485

JAMA Network Open 2018;1(6): e183484

18-10-2018 | Neurology | News | Article

Positive initial results for IGF-1 pathway as treatment target in spinal and bulbar muscular atrophy

The insulin-like growth factor-1 pathway may be a suitable treatment target for patients with spinal and bulbar muscular atrophy, suggest preliminary findings.


Lancet Neurol 2018; doi:10.1016/S1474-4422(18)30320-X

Lancet Neurol 2018; doi:10.1016/S1474-4422(18)30359-4

11-10-2018 | Neurology | News | Article

Editor's pick

Anticoagulants could stave off increased risk of dementia associated with AF

Study findings show an increased risk of dementia in older people with atrial fibrillation and support the use of anticoagulants to reduce the likelihood.


Neurology 2018; doi:10.1212/WNL.0000000000006456

Neurology 2018; doi:10.1212/WNL.0000000000006458

04-10-2018 | Neurology | News | Article

Global burden of Parkinson’s disease is on the rise

The global burden of Parkinson’s disease has more than doubled over the past 26 years, show findings from the Global Burden of Disease Study 2016.


Lancet Neurol 2018; doi:10.1016/S1474-4422(18)30295-3

Lancet Neurol 2018; doi:10.1016/S1474-4422(18)30355-7

27-09-2018 | Neurology | News | Article

Reclassification of juvenile Huntington’s disease may be required

A retrospective analysis of a cohort of children and adolescents with Huntington’s disease points to the presence of two juvenile forms that have markedly different clinical features and prognosis.


Lancet Neurol 2018; doi:10.1016/S1474-4422(18)30294-1

20-09-2018 | Alzheimer's disease | News | Article

Flortaucipir PET discriminates AD from other neurodegenerative disorders

The positron emission tomography tracer [18F]flortaucipir could be a useful test for distinguishing Alzheimer’s disease from other neurodegenerative disorders, say researchers.


JAMA 2018; 320: 1151–1162

13-09-2018 | Multiple sclerosis | News | Article

Fingolimod shows relapse benefits versus interferon beta-1a in paediatric multiple sclerosis

Adolescents with multiple sclerosis may experience fewer relapses if they take fingolimod versus interferon beta-1a, suggest findings from the phase III PARADIGMS trial.


New Engl J Med 2018; 379: 1017–1027

New Engl J Med 2018; 379: 1085–1086

06-09-2018 | Alzheimer's disease | News | Article

Biomarkers identified for diagnosing AD in patients with Down syndrome

Plasma neurofilament light protein concentrations and cerebrospinal fluid biomarkers are effective for diagnosing Alzheimer’s disease in patients with Down syndrome, say researchers.


Lancet Neurol 2018; doi:10.1016/S1474-4422(18)30285-0
Lancet Neurol 2018; doi:10.1016/S1474-4422(18)30293-X

30-08-2018 | Multiple sclerosis | Highlight | Article

Editor's pick

Ibudilast slows brain shrinkage in progressive multiple sclerosis patients

Ibudilast may slow brain atrophy in patients with progressive multiple sclerosis, show findings from a phase II study.


N Engl J Med 2018; 379: 846–855

23-08-2018 | Neurology | News | Article

Novel MS subtype suggests neurodegeneration and demyelination occur independently

Researchers have discovered a new subtype of multiple sclerosis that features neuronal loss but not demyelination of the brain’s white matter.


Lancet Neurol 2018; doi:10.1016/ S1474-4422(18)30245-X

16-08-2018 | Neurology | News | Article

Recognising the risk of increased suicide following TBI

Findings from a large registry-based study support an increased risk of suicide following traumatic brain injury.


JAMA 2018; 320: 554–556, 580–588

image credits